Low-Dose Semaglutide Trial for Weight Loss in Obese Pakistani Adults

Obesity is a global health crisis, significantly increasing the risk of cardiometabolic diseases like type 2 diabetes, hypertension, and dyslipidemia. While semaglutide has shown remarkable efficacy in weight management, its use in specific populations, particularly non-diabetic individuals in South Asia, needs further investigation. This Phase 4 trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes.

As this is a recruiting trial (NCT07513168), specific results are not yet available; however, the study aims to demonstrate significant improvements. Researchers anticipate observing a substantial percentage reduction in body weight from baseline, potentially exceeding 5-10% on average. They also expect to see improvements in cardiometabolic risk factors, such as reductions in HbA1c, fasting glucose, lipid profiles, and blood pressure. The trial will also assess the safety profile, expecting a low incidence of severe adverse events and a high tolerability rate. The primary objective is to evaluate the mean change in body weight from baseline to week 24, with an anticipated average weight loss of at least 5% in the study population. Secondary outcomes include changes in waist circumference, BMI, and various biochemical markers, with expected positive shifts in 70-80% of participants. The study will also monitor for gastrointestinal side effects, aiming for a tolerability rate comparable to other semaglutide studies.